Laboratory Test May Predict Effectiveness of Erbitux for Cancer Patients

Precision Therapeutics, Inc. presented data demonstrating the use of ChemoFX, a chemosensitivity assay, to predict the effectiveness of cetuximab (ERBITUX) on the colorectal cancer cells of individual patients.
Triangle Business Journal